Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Vipoma 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Solid Tumors 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Insulinoma 1Glucagonoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Gastrinoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Breast Neoplasms 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

atezolizumab 3Docetaxel 3pembrolizumab 2olaparib 2lenvatinib 2Leucovorin 2Irinotecan 2Immune Checkpoint Inhibitors 2Fluorouracil 2Filgrastim 2Capecitabine 2zolbetuximab 1tomivosertib 1spartalizumab 1somatostatin receptor 2 1pralsetinib 1pegylated granulocyte colony-stimulating factor 1necitumumab 1motesanib diphosphate 1ipatasertib 1inavolisib 1entrectinib 1ensartinib 1dapagliflozin 1cobimetinib 1cemiplimab 1cat's claw extract 1balugrastim 1anlotinib 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Solid Tumors × motesanib diphosphate × Clear all
NCT00360867 2015-10-15

An Open Label Treatment Extension Study of AMG 706

Amgen

Phase 2 Terminated
94 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡